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Phase 11 study of high-dose dexamethasone-based
association in acute and delayed high-dose
cisplatin-induced emesis - JCOG study 9413
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T Miyamoto, J Takafuji and T Kodama
Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwanoha 6-5-1, Kashiwa-city, Chiba 277, Japan
Summary Thirty-three patients with lung cancer receiving 80 mg m-2 cisplatin were treated with high-dose dexamethasone (32 mg m-2
on days 1-3,16 mg m-2on day 4 and 8 mg m-2 on day 5) combined with granisetron on day 1 and metoclopramide on days 2-5. Twenty-eight
(85%) patients had no nausea or vomiting on day 1, and 16 (48%) achieved total control on days 1-5 with acceptable toxicity. High-dose
dexamethasone for cisplatin-induced delayed emesis should be further evaluated in a phase IlIl trial.
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Nausea and vomiting are among the most distressing side-effects
feared by patients receiving cancer chemotherapy and are of great
concern in medical oncology (Coates et al, 1983; Favero et al,
1993; Gralla, 1993). Delayed emesis, beginning 24 h after
cisplatin (CDDP) infusion, remains a major problem because it
may persist for several days, leading to dehydration, electrolyte
imbalance and malnutrition (Favero et al, 1993; Gralla, 1993). In
addition, the quality of life is severely affected in patients with
prolonged nausea and vomiting. Although 5-HT3 antagonists have
successfully reduced the incidence of acute emesis, the effective-
ness of these agents in controlling delayed emesis is still contro-
versial (Smyth, 1994; Gebbia et al, 1995). A combination of
dexamethasone (DEX) and metoclopramide (MET) is thought to
be the treatment of choice, but 80% of patients still experience
nausea or vomiting over a period of several days (Kris et al, 1989;
Shinkai et al, 1989; Moreno et al, 1992; Smyth, 1994). We have
conducted a phase II trial to evaluate the efficacy and toxicity of
high-dose dexamethasone for acute and delayed emesis in prepara-
tion for a further comparative phase III trial.
PATIENTS AND METHODS
Patients with histologically or cytologically proven lung cancer
and who were being treated with cisplatin-based chemotherapy
were eligible for the study. They were required to be aged between
15 and 74 years, and to have an Eastern Cooperative Oncology
Group (ECOG) performance status of0-2, no priorchemotherapy,
no history of nausea or vomiting before treatment and adequate
renal and hepatic function as indicated by a serum creatinine
< 1.6 mg dl-', creatinine clearance . 60 ml min-', total bilirubin
< 1.6 mg dl-', GOT and GPT < 2 x the normal value. Patients who
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had poorly controlled brain metastasis, diabetes mellitus, heart
diseases, mental disorders, documented active peptic ulcer within
the preceding 6 months, active infections, type B viral hepatitis or
a history ofhypersensitivity to steroids were excluded. Those who
were scheduled to undergo concurrent chemoradiotherapy or had
received steroid hormones were also ineligible. Signed informed
consent was obtained from all patients. Central registration was
carried out at the Statistical Center ofthe Japan Clinical Oncology
Group (JCOG). The protocol and consent form were approved by
the Clinical Trial Review Committee of JCOG and the Review
Boards and Ethical Committee ofthe National Cancer Center.
Patients received either a combination of CDDP [80 mg mn2
intravenously (i.v.) onday 1] and vindesine (VDS) (3 mg m-2i.v. on
days 1 and 8) with or without mitomycin C (MMC) (8 mg m-2 i.v.
on day 1) or the same dose of CDDP with etoposide (100 mg m-2
i.v. on days 1-3). Antiemetic therapy consisted ofDEX (32 mg m-2
i.v. on days 1-3, 16 mg m-2 on day 4 and 8 mg m-2 on day 5),
granisetron (GRN) (40 ,ug kg-' i.v. on day 1) and MET (10 mg
orally three times daily on days 2-5). One additional dose ofGRN
was allowed on day 1 if nausea or vomiting appeared. Famotidine
(20 mg orally twice daily on days 1-5) was givenprophylactically.
Patients were requested to record the severity of nausea using a
four-point grading scale (none, mild, moderate and severe), the
number ofepisodes ofvomiting and side-effects on a diary card on
days 1-5. A complete blood cell count, serum biochemistry, fasting
bloodglucose and occultblood in stools wereexaminedbefore treat-
ment. Blood glucose was monitored before and 2 hours after break-
fast on days 3 and 6. Thehighest ofthe four values was recorded.
A complete response (CR) was defined as no episodes of
vomiting and a score ofnone on the nausea scale. Theprimary end
point ofthe study was the total control (TC) rate (the percentage of
patients achieving CR on days 1-5).
A two-stage design was used to calculate the sample size.
Assuming that a TC rate of 40% would indicate potential useful-
ness while a rate of 20% would be the lower limit of interest,
a = 0.05 and , = 0.20, the estimated required number ofpatients
was 33 (Simon, 1989).
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Table 1 Patient characteristics (n = 33)
Sex
Male
Female
Age (years)
Median (range)
59 or less
60 or more
Performance status
0
1
2
Stage
IIIA
IIIB
IV
Recurrence after curative resection
Chemotherapy
CDDP (80 mg m-2)NDS/MMC
CDDP (80 mg m-2)NDS
CDDP (80 mg m-2)/ ETOP
100-
- 80
a)
c 60.
c
0 a.
40 a)
a)
E
0 O 201
21
12
57 (40-74)
18
15
3
29
1
Table 2 Toxicity (n = 33)
Toxicity n (%)
Hyperglycaemia
116160 mg dl-' 14 (42)
161-250 mg dl-1 3 (9)
Constipation 24 (73)
Hiccups 20 (61)
Sleepiness 12 (36)
Headache 10 (30)
Dizziness 10 (30)
Restlessness 6 (18)
Tremor 4 (12)
Diarrhoea 4 (12)
12
12
8
29
1
3
67
61
01
_ _ _ _ _ _
Day 1 Day2 Day3 Day4 Day5 Days 1-5
(total control)
Figure 1 Antiemetic efficacy (n = 33). A complete response (CR) was
defined as no episodes of vomiting and a score of none on the nausea scale.
Total control (CR on days 1-5) was achieved in 16 (48%) of 33 patients
RESULTS
Thirty-three of 34 patients registered for the study between April
and December 1995 were evaluable for clinical response and toxi-
city. One patient was excluded because his stools were positiveYor
occult blood before treatment and high-dose DEX was not admin-
istered. Of the 33 patients treated, 12 (36%) were female and 18
(55%) were less than 60 years old. Twenty-nine (88%) patients
received CDDP combined with VDS and MMC (Table 1).
The CR rates were 85% on day 1 and about 60% on days 2-5.
The TC rate was 48% (16 of33) with a95% confidence interval of
32.5-64.8% (Figure 1). However, we observed mild nausea,
lasting 24 h at most, between days 7 and 9 in 4 of the 16 patients
with TC.
Mild hyperglycaemia was observed in 17 (51%) of the 33
patients, but none required treatment. In two (6%) patients, MET
was discontinued because of restlessness and hiccups. Other
toxicities were mild and self-limiting (Table 2).
DISCUSSION
It has been difficult to achieve complete prevention of delayed
nausea and vomiting in patients -treated with cisplatin.
Conventional doses of DEX combined with MET have produced
complete protection from delayed vomiting in 50-75% ofpatients,
whereas complete protection from delayed nausea has been
obtained in only 30-35% (Kris et al, 1989; Shinkai et al, 1989;
Moreno et al, 1992). Furthermore, only about 20% of patients
achieved TC of both delayed nausea and delayed vomiting during
both the acute phase and delayed phase of chemotherapy (Smyth,
1994). The TC rate of48% in this study, therefore, seems clinically
significant and suggests that high-dose DEX is highly effective in
controlling delayed nausea and vomiting.
The dose of DEX administered on days 2-3 has usually been
10-16 mg daily (Kris etal, 1989; Shinkai et al, 1989; Moreno et al,
1992). We decided to use a daily dose of 32 mg of DEX on days
2-3, because we thought that a higher dose of at least twice the
dose used formerly would reveal any difference in the antiemetic
response. The dose of DEX on day 1 was also higher than that
used formerly, as some investigators have recommended that treat-
ment for delayed emesis should begin 16 h after chemotherapy
(Kris et al, 1994).
We observed mild nausea between days 7 and 9 in 4 of 16
patients who did not experience any nausea or vomiting on days
1-5. This phenomenon may be associated with the relatively rapid
discontinuation ofDEX. We therefore recommend slower tapering
offof steroids in further trials.
The safety of high-dose DEX given on the first day of
chemotherapy is well established in an animal study (Aapro et al,
1983) and in clinical studies (Aapro et al, 1981; D'Olimpio et al,
1985). In contrast, little is known about any interaction between
cytotoxic agents and high-dose steroids administered for 3 days or
longer. The side-effects of the antiemetic regimen in this study
were mild and self-limiting, except for extrapyramidal symptoms
in tw'o patients, both of whom discontinued MET. However, the
long duration of steroids should be applied carefully, because the
toxicity ofsteroids, especially fungal infections, may increase with
period of administration.
In conclusion, high-dose DEX combined with oral MET
resulted in a total control of nausea and vomiting through days 1
to 5 in about half of patients who received cisplatin. High-
dose DEX would therefore be a good candidate for a further phase
III trial.
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